Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations

In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.

from Latest Science News -- ScienceDaily https://ift.tt/317NlC5

Comments

Popular posts from this blog

Seismic study reveals key reason why Patagonia is rising as glaciers melt

New method to detect and visualize sperm cells recovered from forensic evidence